Heywood, J. ThomasMunshi, KartikJordan, Timothy R.Muse, EvanFudim, MaratSauer, Andrew J.McDermott, MargaretShah, HirakBhimaraj, ArvindKhedraki, RolaRobinson, Monique R.McCann, PatrickVolz, ElizabethGuha, AshrithJonsson, OrvarBhatt, Kunjan A.Bennett, Mosi K.Benjamin, Terrie AnnGuglin, MayaAbraham, Jacobİnsan ve Toplum Bilimleri Fakültesi, Psikoloji Bölümü2024-04-012024-04-012023Heywood, J. T., Munshi, K., Jordan, T., Muse, E., Fudim, M., Sauer, A. J. ... Abraham, J. (2023). Multicenter registry and test bed for extended outpatient hemodynamic monitoring: The hemodynamic frontiers in heart failure (HF2) initiative. Frontiers in Cardiovascular Medicine, 10, 1-7. https://doi.org/10.3389/fcvm.2023.13214152297-055Xhttps://doi.org/10.3389/fcvm.2023.1321415https://hdl.handle.net/20.500.12154/2769Background: Hemodynamic Frontiers in Heart Failure (HF2) is a multicenter academic research consortium comprised of 14 US institutions with mature remote monitoring programs for ambulatory patients with heart failure (HF). The consortium developed a retrospective and prospective registry of patients implanted with a wireless pulmonary artery pressure (PAP) sensor. Goals/aims: HF2 registry collects demographic, clinical, laboratory, echocardiographic (ECHO), and hemodynamic data from patients with PAP sensors. The aims of HF2 are to advance understanding of HF and to accelerate development of novel diagnostic and therapeutic innovations. Methods: HF2 includes adult patients implanted with a PAP sensor as per FDA indications (New York Heart Association (NYHA) Class III HF functional class with a prior hospitalization, or patients with NYHA Class II or brain natriuretic peptide (BNP) elevation without hospitalization) at a HF2 member site between 1/1/19 to present. HF2 registry is maintained at University of Kansas Medical Center (KUMC). The registry was approved by the institutional review board (IRB) at all participating institutions with required data use agreements. Institutions report data into the electronic registry database using REDCap, housed at KUMC. Results: This initial data set includes 254 patients implanted from the start of 2019 until May 2023. At time of device implant, the cohort average age is 73 years old, 59.8% are male, 72% have NYHA Class III HF, 40% have left ventricular ejection fraction (LVEF) < 40%, 35% have LVEF > 50%, mean BNP is 560 pg/ml, mean N-Terminal pro-BNP (NTproBNP) is 5,490 pg/ml, mean creatinine is 1.65 mg/dl. Average baseline hemodynamics at device implant are right atrial pressure (RAP) of 11 mmHg, pulmonary artery systolic pressure (PASP) of 47 mmHg, pulmonary artery diastolic pressure (PADP) 21 mmHg, mean pulmonary artery pressure (mPAP) of 20 mmHg, pulmonary capillary wedge pressure (PCWP) of 19 mmHg, cardiac output (CO) of 5.3 L/min, and cardiac index (CI) of 2.5 L/min/m2. Conclusion: A real-world registry of patients implanted with a PAP sensor enables long-term evaluation of hemodynamic and clinic outcomes in highly-phenotyped ambulatory HF patients, and creates a unique opportunity to validate and test novel diagnostic and therapeutic approaches to HF.eninfo:eu-repo/semantics/openAccessPulmonary Artery PressurePulmonary HypertensionHeart FailureHemodynamicsRemote monitoringCardioMEMSArticle101710.3389/fcvm.2023.1321415Q21.12E+122-s2.0-8517936223038094114Q3